High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles High altitude medicine & biology/High Alt Med Biol Year : 2022

High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World

Abstract

Champigneulle, Benoit, Ivan Hancco, Richard Renan, Stéphane Doutreleau, Emeric Stauffer, Aurélien Pichon, Julien V. Brugniaux, Hélène Péré, Pierre Bouzat, David Veyer, and Samuel Verges. High-altitude environment and COVID-19: SARS-CoV-2 seropositivity in the highest city in the world. High Alt Med Biol. 22: 000-000, 2021. Background: A reduced coronavirus disease 2019 (COVID-19) diffusion has been suggested in high-altitude areas but remained questionable. Aims of this study were to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity as well as the risk factors associated in La Rinconada, the highest city in the world (5,100-5,300 m), a gold-mining town located in southeastern Peru where >50,000 dwellers live in precarious sanitary conditions. Materials and Methods: We performed a cross-sectional study during a 1-week period in October 2020, using point-of-care lateral flow serological assays allowing detection of antibodies directed against SARS-CoV-2 among voluntary dwellers in La Rinconada. Participants were also questioned about potential occupational and environmental risk factors of COVID-19 occurrence. Results: In a sample of 159 dwellers tested in La Rinconada, 48.4% [95% confidence interval, CI: 40.5-56.4] were seropositive for the SARS-CoV-2. Occurrence of at least one symptom compatible with the COVID-19 over the past 6 months remained the only significant factor associated with SARS-CoV-2 seropositivity (adjusted odds ratio: 3.27; [95% CI: 1.70-6.44]; p < 0.001). Conclusions: The high rate of SARS-CoV-2 seropositivity observed in this small sample of highlanders does not support a protective effect of high-altitude against the COVID-19 spread and demonstrates its large dissemination in vulnerable populations. Clinical Trial Registration number: NCT04604249.
No file

Dates and versions

inserm-03803799 , version 1 (06-10-2022)

Identifiers

Cite

Benoit Champigneulle, Ivan Hancco, Richard Renan, Stéphane Doutreleau, Emeric Stauffer, et al.. High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World. High altitude medicine & biology/High Alt Med Biol, 2022, Online ahead of print. ⟨10.1089/ham.2021.0020⟩. ⟨inserm-03803799⟩
138 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More